首页> 外文期刊>International heart journal >Atorvastatin prevents left ventricular remodeling in spontaneously hypertensive rats.
【24h】

Atorvastatin prevents left ventricular remodeling in spontaneously hypertensive rats.

机译:阿托伐他汀可预防自发性高血压大鼠的左心室重构。

获取原文
获取原文并翻译 | 示例
       

摘要

Statins improve left ventricular (LV) remodeling in spontaneously hypertensive rats (SHRs). This study was designed to investigate the effects of atorvastatin administered in the early stage on LV remodeling in SHRs, and to explore the underlying mechanisms.Sixteen male 8-week-old SHRs were randomized to receive distilled water (SHR-DW) or atorvastatin (SHR-ATV) for 12 weeks. Age-matched male Wistar-Kyoto (WKY) rats gavaged with distilled water served as controls. LV remodeling was evaluated, myocardial CTGF expression levels were detected using Western blotting, and cardiomyocyte apoptosis was detected with the TUNEL method.Compared with WKY and SHR-DW, atorvastatin treatment significantly decreased systolic blood pressure in SHRs; atorvastatin significantly inhibited LV remodeling, as indicated by the reduced LV weight/body weight ratio (SHR-ATV: 4.0 +/- 0.4 versus SHR-DW: 4.7 +/- 0.4 mg/g, P < 0.05), cardiomyocyte diameter (SHR-ATV: 16.2 +/- 2.8 versus SHR-DW: 19.0 +/- 1.0 microm, P < 0.05), and interstitial fibrosis (SHR-ATV: 3.3 +/- 2.1 versus SHR-DW: 4.5 +/- 1.8%, P < 0.05). Compared with WKY, myocardial CTGF expression was significantly increased and cardiomyocyte apoptosis decreased in SHRs. Compared with the SHR-DW group, atorvastatin treatment significantly inhibited myocardial CTGF expression (SHR-ATV: 0.69 +/- 0.21 versus SHR-DW: 1.12 +/- 0.27, P < 0.05) and induced cardiomyocyte apoptosis in SHRs (SHR-ATV: 5.2 +/- 0.6 versus SHR-DW: 1.9 +/- 0.3%, P < 0.05).The results indicate that early-stage administration of atorvastatin effectively prevented LV remodeling in SHRs, and that inhibition of myocardial CTGF expression and induction of cardiomyocyte apoptosis may be the underlying mechanisms.
机译:他汀类药物可改善自发性高血压大鼠(SHRs)的左心室(LV)重塑。本研究旨在调查早期服用阿托伐他汀对SHR左室重构的影响,并探讨其潜在机制。随机将16名8周大的男性SHR接受蒸馏水(SHR-DW)或阿托伐他汀( SHR-ATV)12周。年龄相匹配的雄性Wistar-Kyoto(WKY)大鼠用蒸馏水灌胃作为对照。评估左室重塑,采用蛋白质印迹法检测心肌CTGF表达水平,并通过TUNEL法检测心肌细胞凋亡。与WKY和SHR-DW相比,阿托伐他汀治疗可显着降低SHRs的收缩压。阿托伐他汀可显着抑制左室重构,如左室重量/体重比降低(SHR-ATV:4.0 +/- 0.4相对SHR-DW:4.7 +/- 0.4 mg / g,P <0.05),心肌细胞直径(SHR -ATV:16.2 +/- 2.8 vs. SHR-DW:19.0 +/- 1.0 microm,P <0.05)和间质纤维化(SHR-ATV:3.3 +/- 2.1 vs. SHR-DW:4.5 +/- 1.8%, P <0.05)。与WKY相比,SHRs的心肌CTGF表达明显增加,心肌细胞凋亡减少。与SHR-DW组相比,阿托伐他汀治疗显着抑制了心肌CTGF的表达(SHR-ATV:0.69 +/- 0.21,而SHR-DW:1.12 +/- 0.27,P <0.05),并诱导了SHRs的心肌细胞凋亡(SHR-ATV :5.2 +/- 0.6 vs. SHR-DW:1.9 +/- 0.3%,P <0.05)。结果表明,早期服用阿托伐他汀可有效预防SHRs的左室重构,并抑制心肌CTGF的表达和诱导。心肌细胞凋亡可能是其潜在机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号